Rhenium-188, obtained from an alumina-based tungsten-188/rhenium-188 generator, is actually considered a useful candidate for labeling biomolecules such as antibodies, antibody fragments, peptides, and DNAs for radiotherapy. There is a widespread interest in the availability of labeling procedures that allow obtaining Re-labeled radiopharmaceuticals for various therapeutic applications, in particular for the rhenium attachment to tumor-specific monoclonal antibodies (Mo)Abs for immunotherapy. Different approaches have been developed in order to obtain Re-radioimmunoconjugates in high radiochemical purity starting from the generator eluted [Re]ReO. The aim of this paper is to provide a short overview on Re-labeled (Mo)Abs, focusing in particular on the radiolabeling methods, quality control of radioimmunoconjugates, and their in vitro stability for radioimmunotherapy (RIT), with particular reference to the most important contributions published in literature in this topic.
Nat Rev Cancer. 2015 Jun;15(6):347-60
[PMID:
25998714]
Expert Rev Anticancer Ther. 2002 Oct;2(5):485-93
[PMID:
12382517]
Cancer Biol Ther. 2008 Jul;7(7):1116-27
[PMID:
18535406]
Tumour Biol. 2015 Jun;36(6):4053-62
[PMID:
25926382]
J Nucl Med. 1992 Jun;33(6):1099-109
[PMID:
1597723]
Ther Deliv. 2011 Jun;2(6):675-9
[PMID:
22822500]
Appl Radiat Isot. 1996 Jan;47(1):7-14
[PMID:
8589673]
J Med Chem. 1996 Mar 29;39(7):1361-71
[PMID:
8691466]
Clin Cancer Res. 1999 Oct;5(10 Suppl):2994s-3000s
[PMID:
10541333]
Eur J Nucl Med. 1999 Oct;26(10):1265-73
[PMID:
10541824]
Cancer Res. 1990 Dec 15;50(24):7973-8
[PMID:
2253238]
Mol Imaging Biol. 2010 Apr;12 (2):198-203
[PMID:
19543946]
Br J Cancer. 1989 Sep;60(3):406-12
[PMID:
2789951]
Nucl Med Biol. 2011 Jan;38(1):19-28
[PMID:
21220126]
Appl Radiat Isot. 2014 Sep;92 :25-31
[PMID:
24973465]
Comput Math Methods Med. 2015;2015:284360
[PMID:
26136812]
Cancer. 1994 Feb 1;73(3 Suppl):761-8
[PMID:
8306257]
Molecules. 2016 Sep 30;21(10 ):
[PMID:
27706035]
Anticancer Agents Med Chem. 2007 May;7(3):367-77
[PMID:
17504162]
Nucl Med Biol. 1998 Oct;25(7):621-31
[PMID:
9804043]
J Nucl Med. 2001 Jan;42(1):146-53
[PMID:
11197965]
Eur Urol. 2016 May;69(5):767-70
[PMID:
26706103]
J Nucl Med. 1993 Feb;34(2):260-7
[PMID:
8429345]
Nucl Med Biol. 1999 Jan;26(1):57-62
[PMID:
10096502]
J Skin Cancer. 2013;2013:828329
[PMID:
23365757]
Q J Nucl Med. 1996 Jun;40(2):151-60
[PMID:
8909100]
Curr Radiopharm. 2013 Sep;6(3):137-45
[PMID:
24106999]
Bioconjug Chem. 1992 Mar-Apr;3(2):91-9
[PMID:
1515475]
Pharmaceuticals (Basel). 2017 Jan 19;10 (1):
[PMID:
28106830]
Int J Rad Appl Instrum B. 1986;13(4):465-77
[PMID:
3793504]
Cancer Res. 1991 Jan 15;51(2):676-81
[PMID:
1845957]
Appl Radiat Isot. 2001 Mar;54(3):399-406
[PMID:
11214873]
J Nucl Med. 2000 May;41(5):887-95
[PMID:
10809205]
Nucl Med Biol. 2011 Feb;38(2):207-13
[PMID:
21315276]
Inorg Chem. 2012 Mar 5;51(5):3130-7
[PMID:
22324784]
